An enzymatic method for the consistent production of monodispersed viable cell suspensions from human solid tumors

1985 ◽  
Vol 28 (2) ◽  
pp. 131-133 ◽  
Author(s):  
Guo Huang Rong ◽  
Elizabeth A. Grimm ◽  
William F. Sindelar
Keyword(s):  
Solid Tumors ◽  
Viable Cell ◽  
Cell Suspensions ◽  
Enzymatic Method ◽  
Human Solid Tumors

scholarly journals Large hypomethylated blocks as a universal defining epigenetic alteration in human solid tumors

2014 ◽  
Vol 6 (8) ◽  
Author(s):  
Winston Timp ◽  
Hector Corrada Bravo ◽  
Oliver G McDonald ◽  
Michael Goggins ◽  
Chris Umbricht ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Epigenetic Alteration ◽  
Human Solid Tumors

Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges

2013 ◽  
Vol 31 (15) ◽  
pp. 1874-1884 ◽  
Author(s):  
Rodrigo Dienstmann ◽  
Jordi Rodon ◽  
Jordi Barretina ◽  
Josep Tabernero
Keyword(s):  
Solid Tumors ◽  
Cancer Progression ◽  
Cancer Genomics ◽  
Genomic Medicine ◽  
Genomic Data ◽  
Cost Effective ◽  
Assessment Model ◽  
Historical View ◽  
Systemic Treatments ◽  
Human Solid Tumors

Recent discoveries of genomic alterations that underlie and promote the malignant phenotype, together with an expanded repertoire of targeted agents, have provided many opportunities to conduct hypothesis-driven clinical trials. The ability to profile each unique cancer for actionable aberrations by using high-throughput technologies in a cost-effective way provides unprecedented opportunities for using matched therapies in a selected patient population. The major challenges are to integrate and make biologic sense of the substantial genomic data derived from multiple platforms. We define two different approaches for the analysis, interpretation, and clinical applicability of genomic data: (1) the genomically stratified model originates from the “one test-one drug” paradigm and is currently being expanded with an upfront multicategorical approach following recent advances in multiplexed genotyping platforms; and (2) the comprehensive assessment model is based on whole-genome, -exome, and -transcriptome data and allows identification of novel drivers and subsequent therapies in the experimental setting. Tumor heterogeneity and evolution of the diverse populations of cancer cells during cancer progression, influenced by the effects of systemic treatments, will need to be addressed in the new scenario of early drug development. Logistical issues related to prescreening strategies and trial allocation, in addition to concerns in the economic and ethical domains, must be taken into consideration. Here we present a historical view of how increased understanding of cancer genomics has been translated to the clinic and discuss the prospects and challenges for further implementation of a personalized treatment strategy for human solid tumors.

Sign in / Sign up

Export Citation Format

Share Document